Orion Oyj Class B

Orion is a global pharmaceutical company headquartered in Espoo, Finland. The company develops, manufactures and markets human and veterinary pharmaceuticals, as well as active pharmaceutical ingredients and is constantly researching new drugs and treatment methods. Orion’s core therapy areas include central nervous system (CNS) disorders, oncology, and respiratory diseases for which Orion develops inhaled Easyhaler® pulmonary drugs. The company mainly serves consumers with pets, healthcare service providers and professionals such as specialists and general practitioners, veterinarians, pharmacies, hospitals, healthcare centres, clinics and laboratories. Orion operates mainly in Finland, where all of its manufacturing plants and most of its R&D operations are located. Its products are marketed in over a hundred countries, with company sales organisations that cover almost all key European markets. The company also sells its products in other markets through several collaboration partners. Orion’s A and B shares are listed on Nasdaq Helsinki. The company’s financial results for the first half-year of fiscal 2019 include net sales of €493 million. Follow and trade ORNBV.HE for more news and updates.